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Abstract
Severe peripartum hemorrhage (PPH) contributes to
maternal morbidity and mortality and is one of the most
frequent emergencies in obstetrics, occurring at a prev-
alence of 0.5–5.0%. Detection of antepartum risk factors
is essential in order to implement preventive measures.
Proper training of obstetric staff and publication of rec-
ommendations and guidelines can effectively reduce the
frequency of PPH and its resulting morbidity and mor-
tality. Therefore, an interdisciplinary expert committee
was formed, with members from Germany, Austria, and
Switzerland, to summarize recent scientific findings. An
up-to-date presentation of the importance of emboliza-
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tion and of the diagnosis of coagulopathy in PPH is
provided. Furthermore, the committee recommends
changes in the management of PPH including new sur-
gical options and the off-label use of recombinant factor
VIIa.
Keywords: Disseminated intravascular coagulation; peri-
partum hemorrhage; ultrasonography; uterotonic.
Background
Severe peripartum hemorrhage (PPH) is one of the most
life-threatening emergencies in obstetrics. In conjunction
with thromboembolism, PPH is one of the main causes
of maternal death and is observed in 25% of pregnancy-
related complications w9x. PPH contributes to the death
of approximately 140,000 women worldwide, notwith-
standing the considerable number of unreported cases.
Worldwide, a woman dies from postpartum hemorrhage
every four minutes w2x. In the USA and Europe, 1–2
maternal deaths per 100,000 live-births due to hemor-
rhage are expected; with life-threatening peripartum
hemorrhage affecting every 1:1000 births w9x. According
to perinatal statistics, a blood loss of )1000 mL is
expected in 0.5–5% of vaginal deliveries w4, 39, 55x. This
prevalence has been markedly reduced by recommen-
dations and guideline publications and the training of
obstetric staff.
Peripartum blood loss following vaginal birth or cesa-
rean section is often not measured and therefore may be
significantly underestimated w14, 16x. The blood volume
of a pregnant woman is approximately 9% of her total
body weight. The WHO defines PPH as blood loss
)500 mL following vaginal birth or blood loss)1000 mL
following delivery by cesarean section. Severe bleeding
is defined as follows w39, 64x:
– Blood loss )150 mL/min over 20 min; or
– Loss of 50% of circulating blood volume within 3 h;
or
– Acute blood loss )1500–2000 mL.
Distinction of the time of bleeding is made between
early postpartum bleeding (within 24 h following birth)
and late postpartum bleeding (24 h to 6 weeks following
birth). From a clinical perspective, blood loss of
500–1500 mL is generally tolerated without symptoms of
shock w9x.
Symptoms of hemorrhagic shock in cases of large vol-
umes of blood loss are agitation, clouding of conscious-
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Table 1 Risk factors of PPH.
Antepartum Intra- and postpartum
Placenta – History of placental abruption – Retained placenta w4, 62x
– Placenta previa and its risks as well as history of
cesarean section
– Placenta accreta, increta, percreta w55, 62x
Uterus – Uterine atony in previous pregnancy (risk of – Uterine atony w31, 33, 56x
recurrence is up to 25%)
– Previous uterine operations (e.g., c-section,
curettage) – Uterine rupture, inversion of uterus w62x
– Leiomyoma of uterus
– Excessive distension of uterus (e.g., multiple
pregnancy, polyhydramnios, transverse fetal lie)
Coagulation – Acquired coagulation disorder (e.g., drug-induced – Co-morbidity with disseminated intravascular
or organ-related thrombopathy, Werlhof’s disease) coagulation (DIC) (e.g., in the case of severe
– Congenital coagulation disorder (e.g., von pre-eclampsia/HELLP syndrome,
Willebrand’s disease, deficiency of individual placental abruption, chorioamnionitis,
coagulation factors, congenital thrombopathy) sepsis and amniotic fluid embolism)
– Other hemostatic disorders (dilution coagulopathy,
hyperfibrinolysis etc.)
Other – Risks of premature placental abruption (pathologic – Prolonged labor w4, 62x
uterine blood flow with high resistance diagnosed – Labor induction and long-lasting oxytocin
by PW Doppler, thrombophilia) administration w62x
– Antepartum bleeding – Macrosomia ()4000 g w4x or large-for-date
– Multiparity ()5 births) w55x baby w62x)
– Gestational hypertension w62x (e.g., – Operative vaginal delivery (in some cases isolated
HELLP syndrome with risk of DIC) atony of the lower uterine segment) w4, 62x
– Chorioamnionitis – Laceration of the birth canal w62x
– Nicotine and Cocaine abuse – Cesarean section (especially emergency section
after prolonged birth) w55x
ness, cold sweat, paleness, tachycardia, hypotension,
hyperventilation and oligoanuria. Pathophysiologically,
severe bleeding can lead to hemorrhagic shock and con-
sumption coagulopathy and/or dilution coagulopathy.
Specifically, severe bleeding (e.g., placental abruption)
and chorioamnionitis, puerperal sepsis, septic abortion,
amniotic fluid embolism can lead to an increased acti-
vation of the coagulation system resulting in disseminat-
ed intravascular coagulation (DIC) and subsequent
consumption coagulopathy w50x.
The objective of the recommendations presented in
this report is to facilitate the prevention and early treat-
ment of PPH in order to reduce maternal morbidity and
mortality.
Risk factors of PPH
Pre-, intra- and postpartum risk factors
In order to identify risk factors for PPH, the patient’s
medical history should be taken early during pregnancy.
The placental location should be documented during ultra-
sonography screening in the 2nd trimester. Implantation
disorders should be taken into consideration, particularly if
the patient had previous uterine operations or a placenta
previa in the current pregnancy. Table 1 summarizes the
antepartum as well as intra- and postpartum risk factors.
Preventive measures for patients at risk for PPH
Every patient with risk factors should be seen antenatally
at the obstetric department where the delivery is
planned. The following guidelines and procedures should
be followed at the clinic:
1. Adequate venous access during delivery for each
patient, large-caliber venous access if bleeding com-
plications occur.
2. Ensure availability of uterotonic agents (oxytocin, e.g.,
Syntocinon, prostaglandins (e.g., sulprostone: Nala-
dor and, if available, misoprostol: Cytotec woff-label
usex).
3. Check logistics:
– Availability of an ‘‘emergency laboratory’’ (blood
count, blood gas analyses (BGA), aPTT, PT or INR,
antithrombin (AT), fibrinogen, possibly platelet
function analyzer.
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Table 2 Threshold values for replacement of red cells, platelets
and coagulation factors in patients with acute or persistent
bleeding (modified and updated from Po¨tzsch et al. 2007 w53x).
Parameter Limits
Hemoglobin 7–8 g/dL
Platelet count -50,000/mL
INR value )1.5*
aPTT )1.5-fold prolongation of normal value
Fibrinogen -1.5 g/L w67x
*Corresponds, e.g., to a PT of-40% with Roche, Dade-Behring
reagent.
– Anesthesiologist on call (in-house).
– Experienced obstetrician on call (in-house).
– Blood bank availability with timely provision of
packed red cells and fresh frozen plasma.
– Check availability of coagulation factors (fibrino-
gen, recombinant factor VIIa (rFVIIa, NovoSeven),
antifibrinolytics).
To prevent harm to the patient, such conditions must
be checked at each obstetric unit, in particular the timely
availability (preferably within 30 min) of blood compo-
nents (e.g., fresh frozen plasma, packed red cells, plate-
lets as well as coagulation factors).
Strategy for the management of severe PPH
1. Measure blood loss (Note: blood loss in clots etc.).
2. Rapidly evaluate the cause of bleeding: palpate
uterine tone, check for incomplete placenta (ultra-
sonographic control, manual or instrumental explo-
ration), exclude trauma of birth canal by speculum.
3. Initiate pharmacotherapy and/or surgical therapy
depending on etiology.
4. Control vital parameters, possibly invasive moni-
toring.
5. Initial volume replacement in order to maintain nor-
movolemia: crystalloid and colloid solutions.
6. Matching of blood, emergency laboratory (blood
count, coagulation, etc.).
7. Order packed red cells and fresh frozen plasma,
prepare as applicable (delivery room or operating
room).
8. If blood loss is critical (see Table 2), administer
packed red cells and fresh frozen plasma, coagu-
lation factors as necessary, e.g., fibrinogen, rFVIIa
and other hemostatic agents (tranexamic acid,
desmopressin).
9. Consider admission to ICU with possibly invasive
monitoring.
10. Timely operative intervention if conservative meas-
ures fail.
Etiology of bleeding
The causes of bleeding fall into four categories (‘‘4T’s’’):
– Tone (postpartum uterine atony).
– Trauma (laceration of the birth canal).
– Tissue (retained placenta and impaired separation).
– Thrombin (decompensation of coagulation,
coagulopathy).
Postpartum atony
The most common cause of PPH is uterine atony
(67–80% of all PPH, 2–8% of all births) w31, 33, 56x.
Recommendations for physicians include:
– Anticipate risk factors (see Table 1).
– Obtain diagnosis: uterine fundus abnormally high and
soft, and primarily intermittent and projectile bleeding.
Note: 500–1000 mL blood may accumulate in the
uterine cavity; discrepancy between visually estimated
blood loss and clinically profound volume deficiency.
– Empty the bladder.
– Mechanical procedures: Massaging the uterus
(endogenous synthesis of prostaglandins), expression
and holding of the uterus in order to improve contrac-
tility, bimanual uterine compression (e.g., Hamilton’s
maneuver).
– Exclude retained products of conception (ultrasonog-
raphy) and birth injuries (speculum). In the case of
uterine rupture, a marked mobility of the uterus may
be palpable and a hematoma or free fluid/clots may
be visible by ultrasonography (often no heavy vaginal
bleeding).
Pharmacological therapy Uterotonic agents should be
administered in accordance with the following guidelines.
All midwifes and obstetricians should be acquainted with
the following, and these guidelines should be included in
the delivery room manual.
a) Intravenous oxytocin (intramuscularly if indicated): Do
not inject more than 6 I.U. slowly undiluted, 3 I.U. as
a bolus, perhaps an additional 3 I.U. fractionated
q10–40 I.U. oxytocin in 500–1000 mL lactated Rin-
ger’s solution by an intravenous drip (the dose will
depend on the uterine effect w2x). Onset of action is
usually within one minute following i.v. administra-
tion, and within 3–5 min following i.m. administration
(10 I.U. max.). Note: dose-dependent hemodynamic
effect of oxytocin is more pronounced with bolus
administration than with short infusion (e.g., 5 I.U.
over 5 min) as a consequence of vasodilatory effect:
reflex tachycardia, increased cardiac output, tempo-
rary decrease in arterial blood pressure w71x. Myo-
cardial ischemia and deaths have been described
w51, 70x. Other side effects include: increase in blood
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pressure, cardiac arrhythmias, flushing, head and
thoracic pain, nausea and vomiting (especially when
a bolus is administered). Minimal effective dose of
oxytocin i.v. (ED90): 0.35 I.U. w10x.
b) Methylergometrine (Methergin): One ampoule (s
1 mL) contains 0.2 mg methylergometrine. According
to Jacobs (2006) w31x, Methergin should not be
administered as an intravenous bolus, and due to its
side effect profile, the intravenous route of adminis-
tration is no longer used. In Germany, it is authorized
as a slow intravenous administration up to 0.1 mg
(half an ampoule) in patients with postpartum hem-
orrhage. Major contraindications: hypertension, pre-
eclampsia/eclampsia, uterine fibroma, ischemic
vascular disease, severe impairment of liver and kid-
ney function, sepsis. Note: an increasing number of
severe maternal complications, e.g., coronary
spasms, cardiac arrhythmias, myocardial infarction
resulting in death, cerebral angiopathy have been
reported w21, 24, 38, 60, 75x.
c) If oxytocin fails, immediate intravenous administra-
tion of sulprostone (Nalador 500): 1 ampoules
500 mg in 500 mL solution for infusion via droplet
infusion pump, initial dose: 1.7 mL/min, up to 8.3
mL/min max as necessary, maintenance dose: 1.7
mL/min. Maximum daily dose: 1500 mg: In Germany,
prostaglandin F2a (Dinoprost, Minprostin F2a) is no
longer authorized for the treatment of uterine atony
or postpartum hemorrhage. Misoprostol (Cytotec)
has been taken off the German market for economic
reasons but is still available in other countries (e.g.,
Switzerland) (Note: off-label use). Dosage: 1000 mg
misoprostol rectally w30, 36, 37, 68x. According to a
Cochrane analysis w42x, there remains insufficient
data providing evidence of an advantage of miso-
prostol compared with other first-line uterotonic
agents.
d) Intrauterine use of prostaglandins: If intravenous
prostaglandin application fails, uterine tamponades
can be successful (e.g., abdominal packs soaked in
sulprostone). In cases of uterine atony, the effect of
such an action is questionable since contractility of
the uterus is impeded and the risk of infection is
increased. In the case of diffuse bleeding from pla-
cental abruption areas, a tamponade can be helpful,
especially as an effective stopgap measure prior to
surgical intervention w2x. Relatively scant data exist
on intracavitary application of sulprostone, and it is
not approved for this application (off-label use). Intra-
myometrial application of sulprostone (e.g., into the
uterine fundus in patients undergoing cesarean sec-
tion) does not comply with marketing authorization.
Another mechanical method to achieve intracavitary
hemostasis is the Bakri balloon (also Sengstaken-Bla-
kemore tube or similar balloon catheter, content approx-
imately 300 mL), however, limited data are available on
its use for postpartum uterine atony. This application sys-
tem enables an additional intracavitary application of ute-
rotonics following intrauterine filling of the balloon; the
balloon can remain in utero for up to 24 h. Use of a bal-
loon catheter in the case of a ‘‘tamponade test’’: If effec-
tive, leave in place for 24 h. If not sufficiently effective:
surgical treatment is required (commonly laparotomy)
w13, 61x.
Surgical measures Surgical measures to preserve the
uterus should be performed if manual treatment and
pharmacotherapy (including tamponade test) fail to treat
PPH. Surgical measures are described below:
a) Uterine compression sutures: The purpose of this
measure is to reduce the placental adhesion surface
and to tamponade the source of bleeding. This
measure is recommended for patients with diffuse
uterine bleeding following spontaneous birth as well
as following a cesarean section. Methods:
– Traditional B-Lynch suture (‘‘brace suture’’, see
Figure 1a), details and modifications of the meth-
od are described in w7, 43x. Haymen et al. pub-
lished a modification with four vertical comp-
ression sutures to prevent the risk of a displace-
ment of the sutures w20, 25x.
– Compression sutures according to Pereira et al.
(2005) w49x: combination of transversal and verti-
cal sutures (Figure 1B).
– Method according to Cho et al. (2000) w11x: entails
square suturing of the entire uterine wall, including
the uterine cavity, around the bleeding area. The
sutures are passed twice transmurally from the
anterior to the posterior wall, with stitches poste-
rior to anterior, which produces squares of 3–4 cm
with local compression of the uterine walls – a
procedure known as ‘‘multiple square suturing’’.
This procedure is also suitable for hemorrhage
from the lower uterine segment (Figure 1C).
– Further methods of suturing e.g.: Z-suture accord-
ing to Kainer et al. (2003) w34x.
b) Abdominal ligation of the uterine artery, rarely results
in complications (fistula between uterine artery and
vein, intraligamentary hematoma, ureteral lesion) w45x
(Figure 1D). There are also individual reports about
transvaginal ligation of the uterine artery w26x. Note:
ureteral lesion.
c) Stepwise uterine devascularisation: ligation of the
ascending and descending branches of the uterine
artery as well as the collaterals from the ovarian artery
w1x.
d) Ligation of the internal iliac artery: this measure is
technically demanding, since exposure of the internal
iliac artery over 3–4 cm is necessary and the artery
has to be ligated twice distal to the dorsal main stem
– approximately 2.5 cm after the bifurcation – without
separation. Prior to ligation, the ureter, the external
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Figure 1 (A) Traditional B-lynch suture according to B-Lynch
w7x. (B) Compression sutures according to Pereira et al. (2005)
w49x. (C) Method according to Cho et al. (2000) w11x. (D) Abdom-
inal ligation of the uterine artery according to O’Leary (1995)
w45x.
iliac artery and the common iliac artery as well as the
internal iliac veins must be identified (Note: injury to
these veins when undermining the arteries).
e) Laparoscopic bilateral application of transitional uter-
ine clips (Yasargil clips), which will be removed via
laparoscopy during the postpartum period (personal
communication A. Schneider, Berlin).
Arterial embolization Embolization of the uterine arter-
ies (reviewed in Royal College of Radiologists and ROC
of Obstetricians and Gynecologists 2001 w57x) has been
used in severe obstetric lacerations, as well as in the
case of abnormalities of placental implantation, uterine
atony, cervical and abdominal pregnancy with an
80–100% success w15, 46, 47, 65, 73, 74, 77x. Emboli-
zation may also be performed as a last resort in women
with persistent diffuse bleeding in the pelvis following
postpartum hysterectomy w6x. Any department of obstet-
rics should clarify whether and within which timeframe
this method is available. Complications include perfora-
tion of the internal iliac artery w47x, uterine and bladder
necrosis w54x, temporary ischemia of the gluteus muscle,
ischialgiform neuropathy and postembolization
syndrome.
Relative contraindications for uterus-preserving
measures Uterus-preserving measures have a relative
contraindication in:
• Patients with extended abnormality of placental
implantation (placenta increta/percreta), in which the
implantation bed of the placenta is opened, with treat-
ment-resistant bleeding or one that involves large por-
tions of the uterine wall.
• Non-reconstructable uterine injury.
• Septic uterus.
Postpartum hysterectomy Hysterectomy should be
performed only when all other available measures
have been exhausted (frequency: approx. 1:2500 births)
w33, 63x. The following should be taken into
consideration:
• Due to the strong vascularization of the uterus (uterine
artery perfusion at term of delivery approx. 500
mL/min) and the difficulty in delimiting the uterus from
the cervix, this operation is demanding.
• The mean blood loss is 2–3 L.
• Supracervical hysterectomy is preferred, the adnexa
should be preserved.
• Placenta previa commonly requires total hyste-
rectomy.
• Morbidity and mortality are high (1% maternal
mortality).
• The decision of whether conservative approaches are
no longer promising and surgical intervention is indis-
pensable, requires consideration about the hemo-
dynamics and coagulation status. The decision to
perform hysterectomy must not be taken too late.
• In order to avoid fatal bleeding, the administration of
packed red cells, fresh frozen plasma, and platelets
as necessary is mandatory prior to surgical interven-
tion (Table 2).
• To avoid hysterectomy, physicians should consider
administration of rFVIIa (off-label use) w3x. However,
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Figure 2 Scheme of deep placental invasion (placenta acreta,
increta, percreta).
administration of rFVIIa must not delay intervention in
critical situations (Appendix).
Retained products of conception or failure of
separation
Retained product of conception Retained products of
conception occur with a frequency of 1:300 births. Clin-
ical signs are increased bleeding following delivery of the
placenta and poor uterine contraction (possibly).
Management:
• Immediate postpartum inspection of the placenta
(possibly second opinion: midwife/obstetrician):
defects of placental surface, bleeding from placental
defects, aberrant vessels into the fetal membranes (to
exclude accessory placental lobe).
• Ultrasonography.
• Therapy: early manual exploration and possibly curet-
tage in order to prevent further blood loss, intravenous
administration of high-dose uterotonic agents.
Failure of placental separation Failures of separation
are the consequence of partial or complete lack of the
maternal decidua, leading to direct contact between vil-
lous chorion and myometrium. Depending on the depth
of invasion, distinction is made between placenta accre-
ta, increta or percreta (up to the serosa or even exceed-
ing the uterine wall; Figure 2). The frequency of this
disorder is between 1:540 and 1:7000 births w44x
(increasing prevalence due to increasing rates of cesa-
rean sections). Twenty percent of cases are associated
with placenta previa.
Antepartum management:
• Anticipate predisposing factors: e.g., previous cesa-
rean section, previous curettage, in patients with
submucous myomas, previous endometritis, myo-
mectomy and retained placenta in a previous
pregnancy.
• Ultrasonography: sonographic features suggestive for
placenta accreta/increta are irregular shapes, placen-
tal lacunae (vascular spaces) within the placenta, thin-
ning of the myometrium overlying the placenta, loss
of retroplacental ‘‘clear space’’, protrusion of the pla-
centa into the bladder, increased vascularity of the
uterine serosa – bladder interface, and, on Doppler
ultrasonography, turbulent blood flow through the
lacunae w12, 48x. Vaginal sonography enables a more
precise assessment of infiltration depth under the
bladder and allows an assessment to be made as to
whether invasion into the cervical stroma is present in
patients with placenta previa. To date, the diagnostic
value of MRI in these cases has not been clarified and
is currently being investigated w12x.
Failure of placental separation after vaginal birth
Placenta adherens, accreta, increta or percreta are caus-
es of failure of separation following vaginal delivery.
Management:
If there is no placental separation within 30 min follow-
ing birth and/or blood loss is )500 mL:
• Ultrasonography, particularly if predisposing factors
are present (see above).
• Exclude placenta incarcerata: empty bladder.
• General or regional anesthesia.
• Manual placental separation and possibly secondary
curettage (ultrasound monitoring may be helpful) w35x.
Concomitantly: high dose administration of i.v. ute-
rotonic agents, single intraoperative i.v. administration
of antibiotics.
• If the placenta is incompletely removed without
increased bleeding, retained products of conception
may be left in utero to be removed at a later date
(even after several weeks) during a second operation
or expelled spontaneously after several weeks with
regular outpatient monitoring w72x.
Avoid inadequate traction of the umbilical cord (abrup-
tion of the umbilical cord).
If the attempt to separate the placenta and curettage
fails and prostaglandin-resistant bleeding persists: timely
surgical intervention (compression sutures or hysterec-
tomy) might be necessary. If circulation is stable and radi-
ological intervention is available, a bilateral uterine
embolization may be considered w46x.
Impairment of placental separation in patients under-
going cesarean section In the case of extended trans-
mural implantation abnormalities, especially in the area
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of the anterior uterine wall (e.g., placenta percreta), large
areas or small foci of placental tissue may show through
under the uterine serosa; large-diameter subserous ves-
sels and lacunae are visible. The following procedure is
possible in the case of extended placental implantation
abnormalities:
1. Cesarean section hysterectomy, particularly in the
case of uncontrolled and severe bleeding from the
placental site (e.g., following focal ‘‘iatrogenic’’ sep-
aration of the placenta).
2. Delivery of the infant without touching the placenta
(e.g., transverse incision of the fundus in the case of
deep placenta percreta located at the anterior wall)
and keeping the placenta in utero.
3. If the intraoperative diagnosis (see above) is con-
firmed, hysterectomy can be performed following
delivery of the baby without trying to detach the
placenta.
4. Focal resection of the affected uterine wall and pres-
ervation of the uterus in cases of local placental
implantation abnormalities w32x.
5. Focal intracavitary Z-sutures to achieve hemostasis
in small bleeding areas.
If the conservative procedure without hysterectomy is
used and the placenta is left in place, the usual uterotonic
agents should be administered. Following delivery of the
baby, the placenta must not be separated manually, but
should be left in place and the uterotomy should be
closed in two layers using interrupted sutures w44, 48x.
Basically, expectant management for several weeks is
possible if the placenta is left in situ as the placenta may
be spontaneously expelled at a later date w27, 44, 72x. In
the case of severe postoperative bleeding resulting from
deliberately leaving the placenta in place and a concom-
itant significant fall in hemoglobin level, a vascular occlu-
sion (transient if necessary) can also be achieved by
embolization or using a balloon catheter in the internal
iliac artery. It remains debatable as to whether this pro-
cedure may help to reduce perioperative blood loss w8, 46x.
A two-stage hysterectomy following a previous cesarean
section with partial uterine involution may be more pre-
dictable and reduce surgical morbidity w44, 46x.
Peripartum injuries
Peripartum injury is the third most common cause of
postpartum bleeding, accounting for approximately 10%
of cases w56x. In addition to uterine rupture, causes
include extended vaginal laceration, cervical injuries,
parametrial bleeding or profuse bleeding from large epi-
siotomies (e.g., in patients with varicose veins).
Management:
– Anticipation of risks (e.g., operative vaginal delivery,
macrosomia, shoulder dystocia).
– Exclusion of other causes of bleeding (e.g., atony).
– Timely availability of anesthesiologist (in-house).
– Optimal view with additional assistance and exact
location of the source of bleeding.
– Early anesthesia in cases of non-compliance or poor
visualization.
– Rapid surgical treatment by an experienced obstetri-
cian in order to minimize blood loss:
Note: incorrect suture technique, omission of the
upper wound angle may lead to formation of hema-
toma with ‘‘occult blood loss ’’ (diagnosis: palpation
and ultrasound).
Coagulopathy
Coagulopathy due to blood loss Coagulopathy due to
blood loss is one of the most common causes of peri-
partum disorders of hemostasis. This is expected when
the blood loss is 1.5 L or more. Replacement of major
blood loss with crystalloid and colloidal solutions as well
as packed red cells leads to dilution with a decline of the
concentration of all coagulation factors and their activity.
Therefore, coagulopathy due to blood loss is almost
always associated with dilution coagulopathy, the extent
of which depends on the type and volume of the replace-
ment fluid, the original concentration of the coagulation
factors and the dynamics of blood loss. If the entire
blood volume is replaced only by red cells, crystalloid
and colloidal solutions, the residual activity of the coag-
ulation factors is between 30 and 40% and sufficient for
hemostasis w17x.
After an approximately 2.5-fold replacement of blood
volume, a clinically relevant thrombocytopenia can be
expected (-50,000/mL) w28x. Fibrin polymerization is dis-
turbed by the interaction with artificial colloids. Moreover,
coagulopathy is favored by hypothermia (e.g., after infu-
sion of volume replacement agents that have not been
pre-warmed prior to application) and acidosis w22x.
DIC and consumption coagulopathy Frequently, dis-
seminated intravascular coagulation (DIC) with subse-
quent consumption coagulopathy in obstetrics results
from:
– Premature placental abruption (possibly combined
with blood loss coagulopathy).
– Serious hypertensive complications of pregnancy:
pre-eclampsia/eclampsia/HELLP syndrome.
– Septic complications (chorioamnionitis).
– Amniotic fluid embolism (rare: 1:13,000 births).
– Extensive tissue laceration.
It is unlikely that a ‘‘dead-fetus syndrome’’ results in a
maternal coagulation disorder.
A DIC with consumption coagulopathy develops as
follows:
474 Henrich et al., Diagnosis and treatment of peripartum bleeding
Article in press - uncorrected proof
– Phase I: activation of the coagulation system (hyper-
coagulability) by entrance of thromboplastic material
(Tissue Factor) into the maternal circulation.
– Phase II: disseminated intravascular coagulation with
consumption of coagulation factors and inhibitors,
reactive hyperfibrinolysis.
– Phase III: consumption coagulopathy with bleeding
and/or micro- and macrothrombogenesis.
– Phase IV: recovery phase, with an initial increase of
fibrinogen concentration followed by an increase of
other coagulation factors (details in Barthels and von
Depka 2003 w5x).
Diagnosis of DIC In addition to the diagnostic para-
meters and threshold values presented in Table 2, the
following parameters are of importance:
– Thromboelastography in whole blood: enables rapid
measurement of fibrin formation and clot assessment
in whole blood as well as polymerization disorders by
fibrin split products or colloids.
– Clot observation test: observation of clot formation in
whole blood, following its transfer into an uncoated
glass vessel/tube or into a syringe (e.g., normal 5-mL-
syringe). A clot will usually form in approximately
8–10 min (shake carefully every 30 s). Dissolution of
the clot after 30–60 min indicates hyperfibrinolysis
w52x.
– D-dimers: As D-dimers are always increased in the
post partum period, serial measurements are required
and the low specificity of this test should be kept in
mind.
A patient suffering from DIC requires intensive care.
Repeated measurements of coagulation parameters
(INR, aPTT, fibrinogen levels, antithrombin concentra-
tions, D-dimers, possible thromboelastrography wTEGx,
blood count) should be performed.
Treatment of hemostatic disorder When treating
patients with coagulopathy timely elimination of the
underlying cause should be the main aim (e.g., immediate
delivery in the case of placental abruption). At the same
time symptomatic treatment of DIC is required. The crit-
ical limits in the case of acute bleeding are summarized
in Table 2. If bleeding persists, the following should be
performed:
1. Adequate volume replacement with warmed crystal-
loid and colloid solutions.
2. Correction of metabolic acidosis, maintenance of
ionized calcium within the normal range, avoidance
of hypothermia.
3. If blood loss is)20% of blood volume, or if the limits
given in Table 2 are reached: administration of
packed red cells and fresh frozen plasma (FFP, ini-
tially 15–20 mL per kg body weight) (Strategy for the
management of severe PPH). In emergency cases
without cross-matching: packed red cells of blood
group 0 rhesus negative and fresh frozen plasma of
the blood group AB.
4. If fresh frozen plasma is not sufficiently effective/not
available:
– Fibrinogen concentrates: replacement with 2–4 g
is generally sufficient. The fibrinogen concentra-
tion should be at least 1.5 g/L following fibrinogen
administration. Administration of 3 g fibrinogen
with a plasma volume of 3 L increases the fibrin-
ogen concentration by approximately 1 g/L. Note:
fibrinogen should be applied only if a pathologi-
cally increased coagulation activity (mostly with
hyperfibrinolysis) no longer persists (difficult to
assess in the acute obstetric situation). An antifi-
brinolytic agent, e.g., 1000 mg tranexamic acid
i.v., should be administered w58, 67x.
– If INR cannot be corrected with fresh frozen plas-
ma, a prothrombin complex concentrate (PCC)
preparation can be administered, e.g., 20 IU/kg
body weight when INR is )1.5. Note: potential
thrombogenic risk by high prothrombin concen-
tration (long half-life) and other factors.
5. Consider timely application of rFVIIa (Figure 3), if
bleeding does not stop or there is a bleeding reaction
in spite of adequate surgical treatment. Note: previ-
ous administration of prothrombin complex concen-
trates (PCCs) due to increased prothrombin
concentration (see above).
6. Thrombocytopenia (-50,000/mL), in patients with
persistent blood loss requiring replacement of red
blood cells, constitutes a compelling indication of
platelet transfusion w23, 53, 58, 66x.
7. If there is evidence of hyperfibrinolysis (clot obser-
vation test, TEG analysis), antifibrinolytics should be
administered (e.g., tranexamic acid at least 1000 mg
i.v.) or considered if hyperfibrinolysis is expected.
8. No heparin should be administered during bleeding
or in the case of increased risk of bleeding (Note:
bleeding increases!). Instead, antithrombin activity
should be adjusted to G70%, and 1000–2000 I.U.
antithrombin administered (e.g., 2000 I.U. in the case
of replacement of the entire blood volume).
9. Hemostatic parameters should be analyzed at least
every 4 h, and more frequently in acute situations
(approximately every 30 min).
Appendix: The use of recombinant factor VIIa
(rFVIIa, NovoSeven)
Mode of action
rFVIIa acts by binding to tissue factor, eliciting subse-
quent activation of coagulation. However, in pharmaco-
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Figure 3 Algorithm for the use of rFVIIa in patients with severe PPH.
Note: The administration of rFVIIa should be considered before the clinical and hemostaseological situation escalates w17x.
logical doses, rFVIIa acts onto the surface of activated
platelets independently of tissue factor with formation of
factor IXa, factor Xa and a thrombin burst. Thrombin
leads to an activation of factor XIII, contributing to the
formation of a stable fibrin clot and protects this clot from
premature dissolution by plasmin. Moreover, resistance
of the clots to subsequent fibrinolysis is achieved by the
thrombin-mediated activation of TAFI (thrombin activable
fibrinolysis inhibitor). rFVIIa does not provoke systemic
activation of coagulation w29x.
Registration
rFVIIa was authorized in 1996 for the treatment of hemo-
philia with inhibitors, and later for congenital factor VII
deficiency and Glanzmann’s thrombasthenia. Since then,
rFVIIa has successfully been used for various indications
which have not yet received official marketing authori-
zation (off-label use). According to the expert panel, the
off-label use must be seen in the context of a therapeutic
attempt in life-threatening situations of women with seri-
ous treatment-resistant obstetric bleeding. The adminis-
tration of rFVIIa would therefore be justified in such
situations.
Off-label use of rFVIIa in obstetrics
• Serious obstetric bleeding refractory to adequate
pharmacotherapy, surgery and blood component ther-
apy (Figure 3).
• rFVIIa does not replace adequate surgical, embolizing
and conventional hemostatic measures w76x; however,
rFVIIa may possibly avoid postpartum hysterectomy.
• The decision to administer rFVIIa is jointly made by
obstetricians, intensive care specialists/anesthesiolo-
gists and, if possible, hemostaseologists.
• The effect of rFVIIa depends on several concomitant
factors. Therefore, the maintenance of the parameters
mentioned in Figure 3 is paramount.
• Informed consent of patient/relatives, if possible.
Contraindications
• Allergic reactions.
• Relative contraindications: thromboembolic compli-
cations within the last six months (pulmonary embo-
lisms, myocardial infarction, cerebrovascular accident,
deep leg vein or pelvic vein thrombosis). In patients
with coronary heart disease, rFVIIa should be admin-
istered only following a risk-benefit assessment.
• Familial thrombophilia without a history of throm-
boembolic events is not a contraindication.
These contraindications are very rare in young, healthy,
pregnant women. rFVIIa may be associated with an
increased risk of thromboembolic events in patients with
a prior history of vascular disease. However, no throm-
boembolic complications due to rFVIIa were described in
140 patients treated with rFVIIa for PPH w3, 19, 69x. In
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other studies published to date, no significant increase
of thromboembolic events were found in the randomized
and placebo-controlled studies on rFVIIa. In previously
healthy patients with serious bleeding, the risk seems to
be low even in patients with DIC w41x. Following admin-
istration of rFVIIa for PPH, it is recommended to monitor
the patient for thromboembolic events.
Dosage
To date, no recommendations for dose and intervals of
administration/repeated doses exist in obstetrics w18,
19x. Sixty to 120 mg/kg body weight rFVIIa are commonly
administered as i.v. bolus. If severe bleeding persists, a
second bolus of 60–120 mg/kg body weight rFVIIa may
be administered following a period of 15 min to a maxi-
mum time of 60 min.
Criteria for success
Based on case reports, a 75% success rate for the
administration of rFVIIa results when the following criteria
are used:
• Marked reduction of bleeding/cessation of bleeding
(clinically).
• No further blood transfusions.
• Uterine preservation.
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